Boston - GreenLight Biosciences raises $17M to ramp mRNA production

Automatic TRANSCRIPT

A biotech company in Medford that specializes in RNA based products for the agriculture and pharmaceutical industries is shifting its focus toward the effort to develop and manufacture an effective vaccine for covert nineteen greenlight biosciences announced this week that it raised seventeen million dollars to build out its messenger RNA production capabilities with the goal of eventually being able to facilitate the manufacturing of billions of doses of Culver nineteen vaccine using the company's proprietary bioprocessing technology the company does caution though there are very early days of this and the approach is still new for vaccine development and that developing a safe and effective vaccine could take up to a year and a

Coming up next